Table 3.
Relative risk of late death for sickle cell disease
Variable | Hazard Ratio (95% confidence interval) | p-value |
---|---|---|
Age (10-year increment) | 1.75 (1.29 – 2.40) | 0.0004 |
Donor type | ||
HLA-matched sibling | 1.00 | |
Alternative donor | 3.49 (1.53 – 7.96) | 0.0030 |
Sex | ||
Male | 1.00 | |
Female | 1.01 (0.47 – 2.15) | 0.98 |
Performance score | ||
90 – 100 | 1.00 | |
≤ 80 | 1.31 (0.53 – 3.22) | 0.56 |
CMV serostatus | ||
Negative | 1.00 | |
Positive | 1.74 (0.68 – 4.42) | 0.25 |
Conditioning regimen intensity | ||
Myeloablative | 1.00 | 0.22 |
Reduced-intensity | 1.55 (0.58 – 4.12) | 0.38 |
Non-myeloablative | 0.44 (0.11 – 1.74) | 0.24 |
Graft type | ||
Bone marrow | 1.00 | 0.44 |
Peripheral blood | 1.46 (0.59 – 3.61) | 0.41 |
Umbilical cord blood | 0.59 (0.16 – 2.24) | 0.44 |
Transplant period | ||
2011 – 2017 | 1.00 | |
2000 – 2010 | 1.12 (0.43 – 2.91) | 0.82 |